Abstract:Membrane proteins are a crucial class of therapeutic targets that remain challenging to modulate using traditional occupancy-driven inhibition strategies or current proteolysis-targeting degradation approaches. Here, we report that the inherent endolysosomal sorting machinery can be harnessed for the targeted degradation of membrane proteins. A new degradation technique, termed signal-mediated lysosome-targeting chimeras (SignalTACs), was developed by genetically fusing the signaling motif from the cation-independent mannose-6-phosphate receptor (CI-M6PR) to a membrane protein binder. Antibody-based SignalTACs were constructed with the CI-M6PR signal peptides fused to the C-terminus of both heavy and light chains of IgG. We demonstrated the scope of this platform technology by degrading five pathogenesis-related membrane proteins, including HER2, EGFR, PD-L1, CD20, and CD71. Furthermore, two simplified constructs of SignalTACs, nanobody-based and peptide-based SignalTACs, were created and shown to promote the lysosomal degradation of target membrane proteins. Compared to the parent antibodies, SignalTACs exhibited significantly higher efficiency in inhibiting tumor cell growth both in vitro and in vivo. This work provides a simple, general, and robust strategy for degrading membrane proteins with molecular precision and may represent a powerful platform with broad research and therapeutic applications.

An Aptamer Glue Enables Hyperefficient Targeted Membrane Protein Degradation

Bispecific Aptamer Chimeras Enable Targeted Protein Degradation On Cell Membranes

Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Aptamer-Based Targeted Protein Degradation.

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins

Molecular glue degrader for tumor treatment

Chemical Tailoring of Aptamer Glues with Significantly Enhanced Recognition Ability for Targeted Membrane Protein Degradation

Conditionally Activatable Chimeras for Tumor-Specific Membrane Protein Degradation

Frontispiece: Aptamer‐LYTACs for Targeted Degradation of Extracellular and Membrane Proteins

Multivalent Aptamer‐Based Lysosome‐Targeting Chimeras (LYTACs) Platform for Mono‐ or Dual‐Targeted Proteins Degradation on Cell Surface

Targeted Protein Degradation Induced by HEMTACs Based on HSP90

Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic

Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors

Therapeutic antibody engineering for efficient targeted degradation of membrane proteins in lysosomes

Molecular Glues For Targeted Protein Degradation: From Serendipity To Rational Discovery

Advances in molecular glues: exploring chemical space and design principles for targeted protein degradation

Degradation of Extracellular and Membrane Proteins in Targeted Therapy: Status Quo and Quo Vadis.

Targeted protein degradation in drug development: Recent advances and future challenges

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins